EFFICACY OF SOFOSBUVIR IN COMBINATION WITH DACLATASVIR FOR THE TREATMENT OF HEPATITIS C GENOTYPE 3A PATIENTS IN A TERTIARY CARE CENTER IN PAKISTAN
Main Article Content
Keywords
Hepatitis C, Genotype 3a, Daclatasvir, Sofosbuvir
Abstract
Patients with recurring illnesses of the hepatitis C virus frequently develop chronic liver disease, which causes tissue destruction ranging from cirrhosis to hepatocellular carcinoma (HCC). Hepatic-linked deceases are a result of this, both locally and globally. The efficacy of Sofosbuvir (SOF) and Daclatasvir (DCV) for treating individuals per enduring hepatitis C virus genotype 3a infection in either treatment-experienced or treatment-naive patients was examined in the study that was described below. At the Ziauddin Hospital North campus, a retrospective cohort research was carried out over 24 months, from January 2016 to December 2018. Regardless of the history of liver cirrhosis or behavior, patients with Genotype 3a HCV were treated for 12 weeks with Daclatasvir and Sofosbuvir.. Real-time PCR was cast-off to estimate the Sustained Virological Response (SVR12) 12 weeks following therapy. To do the statistical analysis, using SPSS version 20.0. In the study, there were 119 patients total, of which 79 (41.36%) were male, and 112 (58.63%) were girlish. The patient's normal age stood 43.72 13.05. One hundred eighty-two patients (95.28%) had SVR12. Forty patients reported minimal side effects (18.32%). In conclusion, SOF with DCV is an excellent regimen for the genotype 3a virus and highly successful treatment for chronic HCV.
References
2. Gower, E., Estes, C., Blach, S., Razavi-Shearer, K., & Razavi, H. (2014). Global epidemiology and genotype distribution of the hepatitis C virus infection. Journal of hepatology, 61(1), S45-S57.
3. Arshad, A., & Ashfaq, U. A. (2017). Epidemiology of hepatitis C infection in Pakistan: current estimate and major risk factors. Critical Reviews™ in Eukaryotic Gene Expression, 27(1).
4. Butt, N., Anoshia, M. A. K., & Akbar, A. (2021). Effectiveness of Sofosbuvir and Daclatasvir in treatment of Hepatitis-C: An experience of tertiary care hospital in Karachi. Pakistan Journal of Medical Sciences, 37(7), 2014.
5. Charatcharoenwitthaya, P., Wongpaitoon, V., Komolmit, P., Sukeepaisarnjaroen, W., Tangkijvanich, P., Piratvisuth, T., ... & Tanwandee, T. (2020). Real-world effectiveness and safety of sofosbuvir and nonstructural protein 5A inhibitors for chronic hepatitis C genotype 1, 2, 3, 4, or 6: a multicentre cohort study. BMC gastroenterology, 20(1), 1-15.
6. Nelson, D. R., Cooper, J. N., Lalezari, J. P., Lawitz, E., Pockros, P. J., Gitlin, N., ... & ALLY‐3 Study Team. (2015). All‐oral 12‐week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype three infections: ALLY‐3 phase III study. Hepatology, 61(4), 1127-1135.
7. Sial, N., Rehman, J.U., Saeed, S., Ahmad, M., Hameed, Y., Atif, M., Rehman, A., Asif, R., Ahmed, H., Hussain, M.S. and Khan, M.R., 2022. Integrative analysis reveals methylenetetrahydrofolate dehydrogenase 1-like as an independent shared diagnostic and prognostic biomarker in five different human cancers. Bioscience Reports, 42(1), BSR20211783.
8. Panel, A. I. H. G. (2018). Hepatitis C guidance 2018 update: AASLD-IDSA recommendations for testing, managing, and treating hepatitis C virus infection. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America, 67(10), 1477.
9. Usman, M., Hameed, Y., Ahmad, M., Iqbal, M.J., Maryam, A., Mazhar, A., Naz, S., Tanveer, R., Saeed, H., Ashraf, A. and Hadi, A., 2023. SHMT2 is associated with tumor purity, CD8+ T immune cells infiltration, and a novel therapeutic target in four different human cancers. Current Molecular Medicine, 23(2), 161-176.
10. Leroy, V., Angus, P., Bronowicki, J. P., Dore, G. J., Hezode, C., Pianko, S., ... & Thompson, A. J. (2016). Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype three and advanced liver disease: a randomized phase III study (ALLY‐3+). Hepatology, 63(5), 1430-1441.
11. Lontok, E., Mani, N., Harrington, P. R., & Miller, V. (2013). Closing in on the target: sustained virologic response in hepatitis C virus genotype one infection response-guided therapy. Clinical infectious diseases, 56(10), 1466-1470.
12. Sial, N., Ahmad, M., Hussain, M.S., Iqbal, M.J., Hameed, Y., Khan, M., Abbas, M., Asif, R., Rehman, J.U., Atif, M. and Khan, M.R., 2021. CTHRC1 expression is a novel shared diagnostic and prognostic biomarker of survival in six different human cancer subtypes. Scientific reports, 11(1), 19873.
13. Feld, J. J., Maan, R., Zeuzem, S., Kuo, A., Nelson, D. R., Di Bisceglie, A. M., ... & Fried, M. W. (2016). Effectiveness and safety of sofosbuvir-based regimens for chronic HCV genotype three infections: results of the HCV-TARGET Study. Clinical Infectious Diseases, 63(6), 776-783.
14. Usman, M., Okla, M.K., Asif, H.M., AbdElgayed, G., Muccee, F., Ghazanfar, S., Ahmad, M., Iqbal, M.J., Sahar, A.M., Khaliq, G. and Shoaib, R., 2022. A pan-cancer analysis of GINS complex subunit 4 to identify its potential role as a biomarker in multiple human cancers. American Journal of Cancer Research, 12(3), 986.
15. Morio, K., Imamura, M., Kawakami, Y., Nakamura, Y., Kataoka, M., Morio, R., ... & Hiroshima Liver Study Group. (2018). Advanced liver fibrosis effects on the response to sofosbuvir‐based antiviral therapies for chronic hepatitis C. Journal of Medical Virology, 90(12), 1834-1840.
16. Kanwal, F., & Singal, A. G. (2019). Surveillance for hepatocellular carcinoma: current best practice and future direction. Gastroenterology, 157(1), 54-64.
17. Butt, N., Anoshia, M. A. K., & Akbar, A. (2021). Effectiveness of Sofosbuvir and Daclatasvir in treatment of Hepatitis-C: An experience of tertiary care hospital in Karachi. Pakistan Journal of Medical Sciences, 37(7), 2014.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in JPTCP are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.
Sohail Hussain, MBBS, FCPS
Dr. Ziauddin University Hospital, Karachi, Pakistan.
Sm Qamrul Arfin, MBBS, FRCP
Dr. Ziauddin University Hospital, Karachi, Pakistan.
Imtiaz Begum, MBBS, MRCP
Dr. Ziauddin University Hospital, Karachi, Pakistan.
Syed Ali Raza, MBBS, FCPS
Dr. Ziauddin University Hospital, Karachi, Pakistan.
Tauseef Ahmed, MBBS, FCPS
Dr. Ziauddin University Hospital, Karachi, Pakistan.
Jamil Muqtadir, MBBS, FCPS
Dr. Ziauddin University Hospital, Karachi, Pakistan.